Pancreatic Cancer Research

ResearcherUniversity of Florida HealthActive in the last 2 years

Kelly M. Herremans

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0454-0931; OpenAlex author ID A5013850459. Sources: OpenAlex.

Their work

Papers
20 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 6 papers · 2023: 8 papers · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 20

  1. Neoadjuvant Radiation is Causally Linked to Increased Operative Time and Perioperative Blood Transfusion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2026.01.031↗
  2. Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma. First author DOI 10.1002/jcsm.13390↗
  3. Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review. Co-author DOI 10.1136/bmjopen-2023-083696↗
  4. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer. First author DOI 10.1371/journal.pone.0297325↗
  5. A peek at the other side of the coin: Tumor-suppressor role of microRNAs expressed by pancreatic cancer-associated fibroblasts. Co-author DOI 10.1002/ctm2.1357↗
  6. Impact of Biopsy Attempts, Race, and Access on Time to Initiation of Treatment for Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05531-6↗
  7. In vivo models of pancreatic ductal adenocarcinoma. First author DOI 10.1016/bs.acr.2023.02.002↗
  8. A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.06.007↗
  9. Ethical Considerations of Biopsies in Early-Stage Pancreatic Cancer. Co-author DOI 10.1200/op.23.00044↗
  10. Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients. Co-author DOI 10.1371/journal.pone.0281182↗
  11. Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers15184464↗
  12. Translocation of Oral Microbiota into the Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. First author DOI 10.3390/microorganisms11061466↗
  13. A multi-omics approach identifies pancreatic cancer cell extracellular vesicles as mediators of the unfolded protein response in normal pancreatic epithelial c… Co-author DOI 10.1002/jev2.12232↗
  14. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2022.100789↗
  15. The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine. Co-author DOI 10.1186/s40168-022-01262-7↗
  16. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. Co-author DOI 10.1200/jco.21.02492↗
  17. From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care. Co-author DOI 10.3389/fonc.2022.1086779↗
  18. Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/thno.73222↗
  19. Diversity and Inclusion in Pancreatic Cancer Clinical Trials. Co-author DOI 10.1053/j.gastro.2021.06.079↗
  20. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. Co-author DOI 10.1002/cam4.3042↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrea N. Riner · 16 shared papers, 2020–2026 · strength 2.93
  2. Steven J. Hughes · 14 shared papers, 2022–2026 · strength 2.77
  3. Jose Gilberto Trevino · 11 shared papers, 2020–2026 · strength 2.00
  4. Song Han · 7 shared papers, 2022–2024 · strength 1.34
  5. Gerik W. Tushoski-Alemán · 6 shared papers, 2022–2024 · strength 1.15
  6. Patrick W. Underwood · 6 shared papers, 2020–2024 · strength 1.03
  7. Ibrahim Nassour · 5 shared papers, 2022–2026 · strength 1.02
  8. Vignesh Vudatha · 5 shared papers, 2022–2024 · strength 0.92
  9. Thomas J. George · 4 shared papers, 2020–2024 · strength 0.66
  10. Christopher E Forsmark · 3 shared papers, 2023 · strength 0.58
  11. Riley P. Bohan · 3 shared papers, 2022–2023 · strength 0.55
  12. Jose Trevino · 2 shared papers, 2023 · strength 0.43
  13. Kelley Lobean McKinley · 2 shared papers, 2022–2023 · strength 0.37
  14. Michael H. Gerber · 2 shared papers, 2022–2023 · strength 0.30
  15. Jordan A. McKean · 1 shared paper, 2026 · strength 0.29
  16. Miles E. Cameron · 2 shared papers, 2020–2022 · strength 0.28
  17. Lauren B. Solberg · 1 shared paper, 2023 · strength 0.22
  18. Robert A. Winn · 1 shared paper, 2021 · strength 0.19
  19. Sarah M. Judge · 1 shared paper, 2024 · strength 0.19
  20. Andrew R. Judge · 1 shared paper, 2024 · strength 0.19
  21. V. Ashutosh Rao · 1 shared paper, 2023 · strength 0.17
  22. Thomas G. Biel · 1 shared paper, 2023 · strength 0.17
  23. Tyler John Loftus · 1 shared paper, 2022 · strength 0.15
  24. Baldev B. Singh · 1 shared paper, 2022 · strength 0.15
  25. Partha P. Banerjee · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.